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Introduction
The patients for whom influenza vaccination is recommended by all health authorities includes those with inborn errors of metabolism (IEMs) [1] . The main reason for this is that IEMs include diseases that are at high risk of metabolic decompensation after the onset of a febrile infectious disease [2] Moreover, some IEMs are associated with a severe underlying disease (such as neurological involvement or concomitant immunodeficiency) that may lead to influenza-related complications [3] . However, preventing influenza in such children is not as simple as in healthy subjects because the administration of vaccine can be followed by adverse events including fever, and this may worsen their fragile metabolic equilibrium [4] . Furthermore, influenza vaccine may be less effective because many IEMs are accompanied by an inefficient immune system [5] .
It has recently been pointed that, although official recommendations strongly suggest that patients with IEMs should receive routine vaccinations using the same schedule as that used for healthy subjects, we know very little about the immunogenicity, safety and tolerability of many vaccines in patients with IEMs [6, 7] . Consequently, studies regarding the effect of the different vaccines in children with IEMs are strongly advocated, particularly in those at high risk of decompensation.
The aim of this study was to collect data concerning the immunogenicity, safety and tolerability of a trivalent inactivated influenza vaccine (TIV) in children with IEMs at risk of decompensation.
Materials and methods

Study population
The study involved 20 children aged 3-18 years (14 males; mean age ± SD 8.5 ± 3.9 years) with IEM at risk of decompensation according to the definition of Kingsley et al. (10 amino acid disorders, seven cases of glycogen storage disease type I, and three of methylmalonic aciduria) [7] , who had been clinically stable for at least three months and were regularly attending the pediatric Written informed consent to participate in the study was obtained from all of the subjects aged ≥7 years, and from the parents or legal guardians.
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Study procedures
All of the subjects received a single dose of a TIV (Fluarix, GlaxoSmithKline Biologicals, Rixensart, Belgium) by means of an injection in the deltoid muscle in November 2012. The subjects were observed for 30 min after the injection, and their parents recorded the occurrence of solicited and unsolicited local symptoms (erythema, swelling/induration, and pain) or systemic symptoms (an axillary temperature of ≥38 • C, irritability, sleepiness, changes in eating habits, vomiting, diarrhea, malaise, muscle ache) for the next 14 days. The symptoms were considered mild if they did not interfere with normal everyday activities, and severe if they prevented them and required medical attention. Adverse reactions were defined as any reaction that persisted for longer than seven days after the vaccination, and serious adverse reactions as any reaction that required medical attention or hospitalisation during the study period.
Laboratory assays
Immunogenicity was evaluated by means of a standard assay of hemagglutination-inhibiting (HI) antibodies to the influenza strains contained in the vaccine [8] . The serum samples were tested in duplicate at an initial dilution of 1:10, and those that were negative for the antibody were assigned an arbitrary titer of 1:5. HI antibody titers were expressed as the reciprocal of the highest serum dilution that completely inhibited hemagglutination. In accordance with the criteria described in the European Medicines Agency (EMA) guideline [9] , humoral immune response was assessed on the basis of the seroconversion rate (defined as the percentage of subjects experiencing at least a 4-fold increase in a seropositive pre-vaccination HI antibody titer, or an increase from <10 to ≥40 in those who were seronegative), the seroprotection rate (defined as the percentage of subjects reaching an HI titer of ≥40), and geometric mean titers (GMTs).
Statistical analysis
The continuous variables are given as mean values ± standard deviation (SD), and the categorical variables as numbers and percentages. The continuous data were analyzed using a two-sided Student's test if they were normally distributed (on the basis of the Shapiro-Wilk statistic), or a two-sided Wilcoxon rank-sum test if they were not. The categorical data were analyzed using contingency table analysis and the chi-squared or Fisher's test, as appropriate. All of the analyses were two-tailed, and p values of 0.05 or less were considered significant. Table 1 shows the immune responses of the two groups after the administration of the vaccine. More than 50% of the patients and controls had baseline specific antibody titers ≥40 upon HI assay against A/H1N1 and A/H3N2 strains, and about 50% of the patients and 40% of the controls had baseline specific antibody titers of ≥40 upon HI assay against the B strain. Four weeks after the administration of the vaccine, the patients and controls respectively had seroconversion rates of 85% and 75% against A/H1N1, 75% and 85% against A/H3N2, and 75% and 80% against the B strain, with no significant difference between the groups. The seroprotection rates were respectively 95% and 85% against A/H1N1, 90% and 95% against A/H3N2, and 90% and 85% against B strain, once again with no significant between-group difference. GMTs and the increase in antibody levels were similarly high in both groups.
Results
Three months after the vaccination, most of the subjects remained seroconverted and were still seroprotected, without any statistically significant difference between the groups. Their GMTs and the increase from baseline remained similarly high in both groups. There were no differences between the patients with different IEM's. Table 2 summarizes the incidence of local and systemic reactions in the two groups during the 14 days after vaccination. In both groups, 15% of the subjects experienced local reactions and 25% systemic reactions. The distribution of the adverse reactions was similar in the two groups, and there were no serious adverse events. Table 1 Immune responses to a trivalent influenza vaccine in children with inborn errors of metabolism (IEMs) at risk of decompensation and healthy controls. 
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Table 2
Summary of local and systemic reactions in the 14 days following vaccination with a trivalent influenza vaccine in children with inborn errors of metabolism (IEMs) at risk of decompensation and healthy controls. There were no significant differences between the two groups.
Adverse events
During the study period, no influenza-like illness was reported in either group, and no metabolic crisis was reported in the patients with IEMs.
Discussion
Our findings indicate that the administration of a TIV seems to evoke an antibody response in children with IEMs potentially associated with immune system deficiency that is no different from that observed in healthy subjects. Most of the enrolled patients had IEMs that have been associated with immune deficiency, such as amino acid disorders (which have been related to cellular immune defects in number and function, and decreased IgG and IgA levels) [10, 11] and methylmalonic aciduria (in which neutropenia, impaired phagocytic chemotaxis, low B and T lymphocyte counts and low IgG levels have all been identified as individual defects in different patients) [12] . However, it has been repeatedly reported that the immunological abnormalities disappear or are significantly reduced when the metabolic defect is corrected because the main cause of the reduced immune activity seems to be the inborn error itself, which may block a metabolic process that is essential for immune function or produce a toxic metabolite that impairs the immune system [1, 6, 7] . This may explain why our patients (all of whom were clinically stable) showed an adequate immune response to TIV that was similar to that observed in the healthy controls.
Moreover, although the patients with IEMs were theoretically at risk of metabolic decompensation, TIV was safe and well tolerated, and there was no difference in the incidence of adverse events between them and the controls. This confirms that the negative effects of vaccines rarely occur in children with stable IEMs but mainly appear in children with unstable metabolic conditions. Children who have been clinically stable for a long time can receive TIV without any increase in the risk of adverse events.
Although these data are preliminary and need to be confirmed in larger study populations, they could be extrapolated when considering the use of TIV use in subjects with IEMs at risk of decompensation other than those included in this study. Given the higher risk of influenza-related complications in children with IEMs, our findings also support the recommendation that they should receive annual influenza vaccinations [7] . Further studies carried in naïve subjects with IEM as well as in children with different metabolic conditions and more pronounced immune deficits will define the best way of using TIV in order to obtain the maximum benefit and establish whether the recommendation should be refined on the basis of the status of the immune system or the risk of catabolic events.
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